Royalty Pharma
RPRX
RPRX
324 hedge funds and large institutions have $9.31B invested in Royalty Pharma in 2023 Q2 according to their latest regulatory filings, with 45 funds opening new positions, 139 increasing their positions, 106 reducing their positions, and 51 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more ownership
Funds ownership: →
less funds holding
Funds holding: →
12% less first-time investments, than exits
New positions opened: 45 | Existing positions closed: 51
14% less capital invested
Capital invested by funds: $10.9B → $9.31B (-$1.56B)
20% less funds holding in top 10
Funds holding in top 10: 10 → 8 (-2)
Holders
324
Holding in Top 10
8
Calls
$21.9M
Puts
$5.29M
Top Buyers
| 1 | +$43.2M | |
| 2 | +$41.3M | |
| 3 | +$34.9M | |
| 4 |
Two Sigma Investments
New York
|
+$29.4M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$28.2M |
Top Sellers
| 1 | -$188M | |
| 2 | -$138M | |
| 3 | -$41.6M | |
| 4 |
RWJF
Robert Wood Johnson Foundation
Princeton,
New Jersey
|
-$35M |
| 5 |
Renaissance Technologies
New York
|
-$16.3M |